Consortium of industrial and academic partners led by Elthera receives Eurostars grant

SCHLIEREN, SCHWEIZ, November 10, 2020 /EINPresswire.com/ — Elthera AG, iCellate Medical AB, Targos GmbH and Prof. Dr. Susanne Sebens at the Institute of Experimental Cancer Research (IET) at the University of Kiel are proud to announce that they have received a non-dilutive grant with a total budget of 2.7 M € from the EUREKA Eurostars programme. The grant will allow the consortium to finalize the preclinical development of Elthera’s proprietary anti-L1CAM antibody and to develop novel L1CAM-based solid and liquid biopsy methods for patient selection and treatment monitoring in clinical trials.

Anne Schmidt, CEO of Elthera, commented: “We are very happy that we could attract such outstanding industry and academic experts for this exciting project. The combination of research excellence in the field of L1CAM biology, innovative diagnostic technologies, and access to primary patient samples will build the foundation for the successful translation of our anti-L1CAM therapy into clinical testing.”